Paper - WANFANG MED ONLINE

You Position: Home > Paper

Classification,prognosis and therapy of cutaneous T cell lymphoma

( views:392, downloads:174 )

Author:: No author available

Journal Title:: INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY

Issue:: 4

DOI:: 10.3760/cma.j.issn.1673-4173.2007.04.004

Key Word:: 淋巴瘤,T细胞,皮肤;分类法;预后;治疗

Abstract：皮肤T细胞淋巴瘤属结外非霍奇金淋巴瘤,以CD4+的记忆性辅助T淋巴细胞在皮肤上的恶性克隆性扩增为特征.其分类采用WHO-EORTC分类.其预后由年龄、TNM分期、临床分期等多种因素决定.皮肤T细胞淋巴瘤的治疗方法多种多样,除了常用的局部外用药物、系统性药物及物理治疗外,目前尚有一些处于临床试验阶段的治疗方法.

Reference

[1]Rein, Willemze,Elaine S, Jaffe,Günter, Burg,etc.WHO-EORTC classification for cutaneous lymphomas.[J].2005,105(10).
[2]Rudolf Stadler,Almut Kremer.Therapeutic Advances in Cutaneous T-Cell Lymphoma (CTCL): From Retinoids to Rexinoids[J].2006,33(1).
[3]Guitart J,Siegel RS,Pandolfino T,etc.Primary cutaneous T-cell lymphoma: review and current concepts.[J].2000,18(15).
[4]Maxwell A, Fung,Michael J, Murphy,Diane M, Hoss,etc.Practical evaluation and management of cutaneous lymphoma.[J].2002,46(3).
[5]Reinhard Dummer.Future Perspectives in the Treatment of Cutaneous T-Cell Lymphoma (CTCL)[J].2006,33(1).
[6]Karen S McGinnis,Jacqueline M Junkins-Hopkins,Glen Crawford,etc.Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms[J].2004,50(3).
[7]R, Willemze,H, Kerl,W, Sterry,etc.EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.[J].1997,90(1).
[8]Scarisbrick JJ.Staging and management of cutaneous T-cell lymphoma.[J].2006,31(2).
[9]Francine Foss.Clinical Experience With Denileukin Diftitox (ONTAK)[J].2006,33(1).
[10]Kim EJ,Hess S,Richardson SK,etc.Immunopathogenesis and therapy of cutaneous T cell lymphoma.[J].2005,115(4).
[11]D.N. Slater.The new World Health Organization classification of haematopoietic and lymphoid tumours: a dermatopathological perspective[J].2002,147(4).
[12]Rakhshandra Talpur,Staci Ward,Narin Apisarnthanarax,etc.Optimizing bexarotene therapy for cutaneous T-cell lymphoma[J].2002,47(5).
[13]Carole L, Berger,Robert, Tigelaar,Justine, Cohen,etc.Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.[J].2005,105.
[14]Youn H, Kim,Howard L, Liu,Serena, Mraz-Gernhard,etc.Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.[J].2003,139(7).
[15]Visco C,Medeiros LJ,Jones D,etc.Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.[J].2002,13(8).
[16]Sean Whittaker.Biological Insights into the Pathogenesis of Cutaneous T-Cell Lymphomas (CTCL)[J].2006,33(1).
[17]Berger CL,Hanlon D,Kanada D,etc.Transimmunization, a novel approach for tumor immunotherapy.[J].2002,26(3).
[18]Laetsch B,Dummer R,Cozzio A,etc.Standard and experimental therapy in cutaneous T-cell lymphomas.[J].2006,33(Suppl.1).
[19]Jorge R, Toro,David J, Liewehr,Nina, Pabby,etc.Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma.[J].2003,101.
[20]Gorgun Akpek,Howard K. Koh,Steven Bogen,etc.Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T‐cell lymphoma[J].1999,86(7).